Dyadic International

DYAI · NASDAQ

$0.3851+$0.0042 (+1.10%)TodayMarket closed · Oct 20, 4:00 PM ET

Prev close $0.3809

Latest news

NewsSep 28, 5:06 PM ET
12 Health Care Stocks Moving In Monday's After-Market Session
NewsSep 9, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
Press releaseAug 12, 8:30 AM ETGlobe Newswire
Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas
Press releaseAug 4, 7:25 AM ETGlobe Newswire
Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement
Press releaseJul 28, 8:30 AM ETGlobe Newswire
Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days
Press releaseJul 24, 7:30 AM ETGlobe Newswire
Dyadic Announces Continued Listing on the Nasdaq Capital Market
Press releaseJul 16, 8:00 AM ETGlobe Newswire
Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program
Press releaseJul 7, 7:25 AM ETGlobe Newswire
Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential
Press releaseJun 29, 7:25 AM ETGlobe Newswire
Dyadic Expands IP Protection and Business Development Activities in Japan
Press releaseJun 15, 7:25 AM ETGlobe Newswire
Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption
Press releaseMay 28, 7:25 AM ETGlobe Newswire
Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development
NewsMay 21, 5:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
Press releaseMay 19, 9:35 AM ETGlobe Newswire
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
NewsMay 13, 5:54 PM ET
Transcript: Dyadic International Q1 2026 Earnings Conference Call
Press releaseMay 13, 4:05 PM ETGlobe Newswire
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
NewsMay 13, 7:11 AM ET
Earnings Scheduled For May 13, 2026
NewsMay 12, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseMar 25, 4:51 PM ETGlobe Newswire
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
NewsMar 25, 7:11 AM ET
Earnings Scheduled For March 25, 2026
NewsDec 1, 7:37 AM ET
Market-Moving News for December 1st
Press releaseNov 12, 4:05 PM ETGlobe Newswire
Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress
NewsAug 12, 2:02 PM ET
A Look at Dyadic International's Upcoming Earnings Report
NewsJul 30, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsJul 29, 5:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseJul 2, 4:00 PM ETBusiness Wire
Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions
NewsMar 19, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsNov 11, 12:01 PM ET
Exploring Dyadic International's Earnings Expectations

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Monday's After-Market Session

12 Health Care Stocks Moving In Wednesday's After-Market Session

Dyadic Announces Second Quarter 2026 Financial Results Accelerating Commercialization Momentum Across Key Business Areas

Dyadic Expands Commercial Non-Animal Dairy Pipeline Through New Strategic Development Agreement

Dyadic Develops Stable C1 Cell Lines and Produces Purified Scripps-Designed Bundibugyo Ebola Antigens from Plasmids in Approximately 15 Days

Dyadic Announces Continued Listing on the Nasdaq Capital Market

Dyadic Expands Bio industrial Pipeline with New Proprietary Industrial Enzyme Program

Global Collaborations Continue to Validate Dyadic’s C1 Platform and Expands Commercial Potential

Dyadic Expands IP Protection and Business Development Activities in Japan

Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption

Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

12 Health Care Stocks Moving In Thursday's After-Market Session

Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference

Transcript: Dyadic International Q1 2026 Earnings Conference Call

Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress

Earnings Scheduled For May 13, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress

Earnings Scheduled For March 25, 2026

Market-Moving News for December 1st

Dyadic Announces Third Quarter 2025 Financial Results and Highlights Strategic Progress

A Look at Dyadic International's Upcoming Earnings Report

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

Dyadic International, Inc. Announces Strategic Rebrand to Dyadic Applied BioSolutions

12 Health Care Stocks Moving In Wednesday's After-Market Session

Exploring Dyadic International's Earnings Expectations